Lawrence O. Klein

2019

In 2019, Lawrence O. Klein earned a total compensation of $6.1M as Chief Business Officer and Chief Operating Officer at CRISPR Therapeutics AG.

Compensation breakdown

Non-Equity Incentive Plan$209,032
Option Awards$1,549,003
Salary$360,400
Stock Awards$3,984,600
Other$9,800
Total$6,112,835

Klein received $4M in stock awards, accounting for 65% of the total pay in 2019.

Klein also received $209K in non-equity incentive plan, $1.5M in option awards, $360.4K in salary and $9.8K in other compensation.

Rankings

In 2019, Lawrence O. Klein's compensation ranked 1,658th out of 13,971 executives tracked by ExecPay. In other words, Klein earned more than 88.1% of executives.

ClassificationRankingPercentile
All
1,658
out of 13,971
88th
Division
Manufacturing
592
out of 5,701
90th
Major group
Chemicals And Allied Products
179
out of 2,200
92nd
Industry group
Drugs
144
out of 1,886
92nd
Industry
Biological Products, Except Diagnostic Substances
33
out of 389
92nd
Source: SEC filing on April 24, 2020.

Klein's colleagues

We found four more compensation records of executives who worked with Lawrence O. Klein at CRISPR Therapeutics AG in 2019.

2019

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2019

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2019

James Kasinger

CRISPR Therapeutics AG

General Counsel

2019

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

News

You may also like